Stem Cell Implant Is Being Trialled To Cure" Type 1 Diabetes – IFLScience

A groundbreaking attempt to"cure" Type 1 diabetes with stem cells began last week. Embryonic stem cell implants were given to two people, one in the US and one in Canada, with high-risk Type 1 diabetes. The researchers hope that this willhelp the patients manage the condition.

The stem cells, developed by private company ViaCyte, are implanted underneath the patient's forearm, where they take about three months to mature into islet cells. In the pancreas, these cells are responsible for the production of insulin. In people with Type 1 diabetes, these cells are attacked by the bodys own immune system.

If it works, we would call it a functional cure, Paul Laikind of Viacyte told New Scientist. Its not truly a cure because we wouldnt address the autoimmune cause of the disease, but we would be replacing the missing cells.

A smaller implant has already been trialled on 19 people for safety and the company expects to extend the trial to 40 more people later this year, in order to understand both the safety and efficacy of the full-size implant. ViaCyte would like to get preliminary results during the first half of 2018 and to know if the system works between six and12 months later.

Islet transplants have been used to successfully treat patients with unstable, high-risk Type 1 diabetes, but the procedure has limitations, including a very limited supply of donor organs and challenges in obtaining reliable and consistent islet preparations, trial investigator James Shapiro, from the University of Alberta, said in a statement. An effective stem cell-derived islet replacement therapy would solve these issues and has the potential to help a greater number of people.

If a success, the implant will improve the lives of the patients as they wont have to closely monitor their blood levels or inject insulin, but there is a trade-off. They will have to take immunosuppressive drugs, so that their bodies dont attack the newly implanted cells. This iswhy the procedure is targeted atpeople who are at ahigher risk.

Researchers estimate that 140,000 people in Canada and the US are currently suffering from high-risk Type 1 diabetes. The condition can lead to severe episodes of hypoglycemia in the short term and heart disease, stroke, and kidney disease (among others) in thelong term.

[H/T:New Scientist]

More:
Stem Cell Implant Is Being Trialled To Cure" Type 1 Diabetes - IFLScience

Lego-Like Brain Balls Could Build a Living Replica of Your Noggin – WIRED

This cerebral organoid, or mini-brain, was grown in a laboratory. It contains a diversity of cell types and internal structures that can make it a good stand-in for an actual brain in experiments. Unpredictable variations and deficiencies have hampered the organoids usefulness in research, but new techniques for creating mini-brains may change that.

Hoffman-Kim lab/Brown University

The human brain is routinely described as the most complex object in the known universe. It might therefore seem unlikely that pea-size blobs of brain cells growing in laboratory dishes could be more than fleetingly useful to neuroscientists. Nevertheless, many investigators are now excitedly cultivating these curious biological systems, formally called cerebral organoids and less formally known as mini-brains. With organoids, researchers can run experiments on how living human brains developexperiments that would be impossible (or unthinkable) with the real thing.

Original story reprinted with permission from Quanta Magazine, an editorially independent publication of the Simons Foundation whose mission is to enhance public understanding of science by covering research developments and trends in mathematics and the physical and life sciences.

The cerebral organoids in existence today fall far short of earning the brain label, mini or otherwise. But a trio of recent publications suggests that cerebral-organoid science may be turning a cornerand that the future of such brain studies may depend less on trying to create tiny perfect replicas of whole brains and more on creating highly replicable modules of developing brain parts that can be snapped together like building blocks. Just as interchangeable parts helped make mass production and the Industrial Revolution possible, organoids that have consistent qualities and can be combined as needed may help to speed a revolution in understanding how the human brain develops.

In 2013 Madeline Lancaster , then of the Austrian Academy of Sciences, created the first true cerebral organoids when she discovered that stem cells growing in a supportive gel could form small spherical masses of organized, functioning brain tissue. Veritable colleges of mini-brains were soon thriving under various protocols in laboratories around the world.

Much to the frustration of impatient experimentalists, however, the mini-brains similarity to the real thing only went so far. Their shrunken anatomies were distorted; they lacked blood vessels and layers of tissue; neurons were present but important glial cells that make up the supportive white matter of the brain were often missing.

Worst of all was the organoids inconsistency: They differed too much from one another. According to Arnold Kriegstein , director of the developmental and stem cell biology program at the University of California, San Francisco, it was difficult to get organoids to turn out uniformly even when scientists used the same growth protocol and the same starting materials. And this makes it very difficult to have a properly controlled experiment or to even make valid conclusions, he explained.

Researchers could reduce the troublesome variability by treating early-stage organoids with growth factors that would make them differentiate more consistently as a less varied set of neurons. But that consistency would come at the expense of relevance, because real brain networks are a functional quilt of cell typessome of which arise in place while others migrate from other brain regions.

For example, in the human cortex, about 20 percent of the neuronsthe ones called interneurons, which have inhibitory effectsmigrate there from a center deeper down in the brain called the medial ganglionic eminence (MGE). An oversimplified organoid model for the cortex would be missing all those interneurons and would therefore be useless for studying how the developing brain balances its excitatory and inhibitory signals.

A stained cross section through one of the cortical organoids created by researchers at the Yale Stem Cell Center shows the organization of various cell types into layers of tissue. The organoid is 40 days old in this image. The blue dots are cell nuclei; the red patches are progenitor cells for neurons; the green patches are differentiated neurons.

Courtesy of Yangfei Xiang

Deliverance from those problems may have arrived with recent results from three groups. They point toward the possibility of an almost modular approach to building mini-brains, which involves growing relatively simple organoids representative of different developing brain regions and then allowing them to connect with one another.

The most recent of those results was announced two weeks ago in Cell Stem Cell by a group based at the Yale Stem Cell Center. In the first stage of their experiments, they used human pluripotent stem cells (some derived from blood, others from embryos) to create separate organoid replicas of the cortex and MGE. The researchers then let mixed pairs of the ball-shaped organoids grow side by side. Over several weeks, the pairs of organoids fused. Most important, the Yale team saw that, in keeping with proper brain development, inhibitory interneurons from the MGE organoid migrated into the cortical organoid mass and began to integrate themselves into the neural networks there, exactly as they do in the developing fetal brain.

Earlier this year, teams from the Stanford University School of Medicine and the Austrian Academy of Sciences published reports on similar experiments in which they too developed cortical and MGE organoids and then fused them. The three studies differ significantly in their detailssuch as how the researchers coaxed stem cells to become organoids, how they nurtured the growing organoids, and what tests they ran on the derived cells. But they all found that the fused organoids yielded neural networks with a lifelike mix of excitatory neurons, inhibitory neurons and supporting cells, and that they could be developed more reliably than the older types of mini-brain organoids.

To Kriegstein, all three experiments beautifully illustrate that the cells in organoids will readily transform into mature, healthy tissue if given the opportunity. Once you coax the tissue down a particular developmental trajectory, it actually manages to get there very well on its own with minimal instruction, he said. He believes that specialized organoids could bring a new level of experimental control to neuroscientists explorations: Scientists could probe different brain organoids for information about development within subregions of the brain and then use that combined or fused platform to study how these cells interact once they start migrating and encountering each other.

In-Hyun Park , an associate professor of genetics who led the Yale study, is hopeful that organoids might already be useful in preliminary investigations of the developmental roots of certain neuropsychiatric conditions, such as autism and schizophrenia. Evidence suggests that in these conditions, Park said, there seems to be an imbalance between excitatory and inhibitory neural activity. So those diseases can be studied using the current model that weve developed.

Emily Singer

A Map of the Brain Could Teach Machines to See Like You

Emily Singer

New Clues to the Mystery of How Our Brains Keep Time

Natalie Wolchover

New Math Untangles the Mysterious Nature of Causality

Kriegstein cautions, however, that no one should rush to find clinical significance in organoid experiments. What we really lack is a gold standard of human brain development to calibrate how well these organoids are mimicking the normal condition, he said.

Whatever applications organoid research may eventually find, the essential next steps will consist of learning how to produce organoids that are even more true to life, according to Park. He has also not given up hope that it will eventually be possible to create a mini-brain in the laboratory that is a more complete and accurate stand-in for what grows in our head. Maybe doing so will involve a more complex fusion of organoid subunits, or maybe it will demand a more sophisticated use of growth media and chemicals for directing the organoid through its embryonic stages. There should be an approach to generating a human brain organoid that is composed of forebrain plus midbrain plus hindbrain all together, Park said.

Jordana Cepelewicz contributed reporting to this article.

Original story reprinted with permission from Quanta Magazine , an editorially independent publication of the Simons Foundation whose mission is to enhance public understanding of science by covering research developments and trends in mathematics and the physical and life sciences.

Read the original post:
Lego-Like Brain Balls Could Build a Living Replica of Your Noggin - WIRED

Dopaminergic neurons derived from iPSCs in non-human primate model – Phys.Org

August 8, 2017 Stem Cells and Development is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. Credit: Mary Ann Liebert, Inc., publishers

Researchers have demonstrated the ability to generate dopaminergic neurons in the laboratory from induced pluripotent stem cells (iPSCs) derived from fibroblast cells of adult marmoset monkeys. This new study, documenting the iPSCs' pluripotent properties and the potential for using this animal model to develop regenerative medicine approaches for dopamine-related disorders such as Parkinson's disease, is published in Stem Cells and Development.

Marina Emborg, MD, PhD and colleagues from University of Wisconsin-Madison coauthored the article entitled "Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Adult Common Marmoset Fibroblasts." The researchers reported that the marmoset fibroblast-derived iPSCs could differentiate into all three embryonic cell lineages: mesoderm, ectoderm, and endoderm. When stimulated to pattern themselves as neurons, the iPSCs expressed genes and other biomarkers consistent with a dopaminergic phenotype.

"This important study advances the marmoset as a model for Parkinson's disease, for the first time deriving a line from the adult marmoset," says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.

Explore further: Stem cell-derived dopaminergic neurons rescue motor defects in Parkinsonian monkeys

More information: Scott C. Vermilyea et al, Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Adult Common Marmoset Fibroblasts, Stem Cells and Development (2017). DOI: 10.1089/scd.2017.0069

Parkinson's disease is a degenerative disorder of the central nervous system that is characterized by tremors, rigidity, slowness of movement, and difficulty walking. It is caused by loss of the neurons that produce the neurotransmitter ...

Highly valuable for modeling human diseases and discovering novel drugs and cell-based therapies, induced pluripotent stem cells (iPSCs) are created by reprogramming an adult cell from a patient to obtain patient-specific ...

Researchers have shown that following a stroke-induced ischemic injury to the human brain, stem cells are produced that have the potential to differentiate and mature to form neurons that can help repair the damage to the ...

Induced pluripotent stem cells (IPSCs) hold great promise in regenerative medicine, personalized medicine and drug discovery. However, while avoiding the ethical controversies associated with embryonic stem cells, they carry ...

A new study demonstrates that iPSC have the potential to differentiate into multiple lineages of functional lymphocytes, including CD4+ T cells, B cells, and natural killer cells, without bias. The ability to generate truly ...

New Rochelle, NY, June 23, 2016 -Replacing dopamine-producing cells in the brain represents a promising therapeutic approach in Parkinson's disease, and a new study shows how post-transplantation gamma-ray irradiation can ...

Biologically speaking, nearly every species on Earth has two opposite sexes, male and female. But with some fungi and other microbes, sex can be a lot more complicated. Some members of Cryptococcus, a family of fungus linked ...

Scientists at the Universities of Oslo and Liverpool have uncovered the secret behind a goldfish's remarkable ability to produce alcohol as a way of surviving harsh winters beneath frozen lakes.

(Phys.org)A team of researchers with the University of Pennsylvania has uncovered the means by which squid eyes are able to adjust to underwater light distortion. In their paper published in the journal Science, the group ...

The gene-editing technology called CRISPR has revolutionized the way that the function of genes is studied. So far, CRISPR has been widely used to precisely modify single-celled organisms and, more importantly, specific types ...

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the current issue of Science, Nikolaus Rajewsky and his team at the ...

In the cells of palm trees, humans, and some single-celled microorganisms, DNA gets bent the same way. Now, by studying the 3-D structure of proteins bound to DNA in microbes called Archaea, University of Colorado Boulder ...

Adjust slider to filter visible comments by rank

Display comments: newest first

My husband is 80 years and has been suffering from PD for the past 15 years. Lately he started hallucinating and I didn't know how to handle the situation. He cannot sleep and tried to find and catch the imaginary people who he thinks are real. he was taken Entacapone with Levodopa, Carbidopa, and Pramipexole and started physical therapy to strengthen muscles. nothing was really working to help his condition.I took him off the Siferol (with the doctor's knowledge) and started him on parkinson's herbal formula i ordered from Health Herbal Clinic, his symptoms totally declined over a 5 weeks use of the Parkinsons disease natural herbal formula.i read reviews from other previous patients who used the herbal formula, my husband is now active, he can now go about daily exercise!! his symptoms so much reduced that now I hardly notice them.Visit there website www. healthherbalclinic. net or email Info@ healthherbalclinic. net

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the article here:
Dopaminergic neurons derived from iPSCs in non-human primate model - Phys.Org

Stem Cell Therapy Selectively Targets and Kills Cancerous Tissue – Anti Aging News

1538 1 Posted on Aug 11, 2017, 6 a.m.

Researchers have created a method to kill cancerous tissue without causing the harmful side effects of chemotherapy.

Medical researchers at the University of California, Irvine have created a stem cell-based method to zero in on cancerous tissue. This method kills the cancerous tissue without causing the nasty side effects of chemotherapy. Such side effects are avoided by treating the disease in a more localized manner. The advancement was spearheaded by associate professor of pharmaceutical sciences Weian Zhao. The details of the stem cell therapy were recently published in Science Translational Medicine.

About the new Stem Cell Therapy

Zhao's team programmed stem cells derived from human bone marrow to pinpoint the specific properties of cancerous tissue. They implemented a portion of code to these engineered cells to identify stiff cancerous tissue, lock onto it and implement therapeutics. The researchers safely used this new stem cell therapy in mice to kill metastatic breast cancer that had moved to the lungs. They transplanted these engineered stem cells in order for the teamto pinpoint and settle in the site of the tumor.

Once the stem cells reached the tumor, they released enzymes referred to as cytosine deaminase. The mice were then provided with an inactive chemotherapy known as prodrug 5-flurocytosine. The tumor enzymes stimulated the chemotherapy into action. Zhao stated his team zeroed in on metastatic cancer that occurs when the disease moves to additional parts of the body. Metastatic tumors are especially dangerous. They are responsible for90 percent of all cancer deaths.

Why the new Stem Cell Therapy is Important

Zhao is adamant his stem cell therapy represents an important newparadigm in the context of cancer therapy. Indeed, Zhao has blazed a trail in a new direction that others will likely follow in the years to come. It is possible his new stem cell therapy serves as an alternative and more effective means of treating cancer. This stem cell therapy will serve as an alternative to numerous forms of chemotherapy that typically have nasty side effects. Chemotherapy certainly kills plenty of growing cancer cells yet it can also harm healthy cells. The new type of treatment keys in on metastatic tissue that allows for the avoidance of the undesirable side effects produced by chemotherapy.

Though the published piece describing this stem cell therapy is centered on breast cancer metastases within thelungs, the method will soon be applicable to additional metastases. This is due to the fact that numerous solid tumors are stiffer than regular tissue. The new system does not force scientists to invest time and effort to pinpoint and create a brand new protein or genetic marker for each kind of cancer.

The Next Step

At this point in time, Zhao's team has performed pre-clinical animal studies to show the treatment is effective and safe. They plan to segue to human studies in the coming months and years. Zhao's team is currently expanding to additional types of cells such as cancer tissue-sensing and engineered immune system CAR-T (T cells) to treat metastasizing colon and breast cancers. Their goal is totransform this technology for the treatment of additional diseases ranging from diabetes to fibrosis and beyond.

Read the original here:
Stem Cell Therapy Selectively Targets and Kills Cancerous Tissue - Anti Aging News

Mutation-directed CAR T cell therapy feasible in recurrent glioblastoma – medwireNews

medwireNews: Treatment with autologous chimeric antigen receptor (CAR) T cells directed against the epidermal growth factor receptor variant III (EGFRvIII) mutation is feasible and well tolerated in patients with recurrent glioblastoma, indicates a first-in-human study.

But barriers to the clinical efficacy of the therapy exist, says the research team, including the inhibitory tumor microenvironment, which becomes even more immunosuppressive after CAR T cells.

Lead author Marcela Maus (Massachusetts General Hospital, Boston, USA) and colleagues chose the EGFRvIII mutation as it is a tumor-specific, oncogenic, and immunogenic epitope expressed in around 30% of newly diagnosed cases of glioblastoma.

In this phase I study, reported in Science Translational Medicine, 10 patients with EGFRvIII-expressing glioblastoma that had progressed after at least one prior line of therapy were given a single infusion of an autologous EGFRvIII-directed CAR T product within a week of progression.

There were no dose-limiting toxicities, and no evidence of off-target EGFR-directed effects such as rash, diarrhea, or pulmonary symptoms or systemic cytokine release syndrome.

Neurologic events were observed in three patients and included a seizure at day 9 in one patient and neurologic decline in two patients, at day 15 in one case and postoperatively in the other. Although such events are common in glioblastoma patients due to the nature of the disease, Maus et al say that they could also result from CAR T-induced immune responses in the confined intracranial space.

They were unable to formally assess efficacy as the majority (n=7) of study participants underwent surgery following infusion of the CAR T cells. But one patient was alive and required no further treatment for 18months or more after the infusion. A further two patients were also alive at the time of analysis, but they showed signs of disease progression by imaging criteria.

The surgical intervention allowed the researchers to evaluate not only tissue-specific trafficking of CAR T cells and on-target effects, but also the tumor microenvironment in situ.

Analysis of tumor samples showed the presence of EGFRvIIICAR T cells in the brain, with higher levels in the four patients who had surgery within 14days of the infusion than in the three who underwent surgery at later timepoints.

And comparison of post-infusion samples with matched samples obtained before the infusion revealed a significant decline in the expression levels of EGFRvIII in five of the seven participants with available samples. Such a decrease in antigen expression in the remaining tumor bed and tissue is indicative of on-target effects, say Maus and colleagues.

But they also found that the expression of several immunosuppressive molecules, including indoleamine 2,3-dioxygenase 1, was markedly increased in post- versus pre-infusion samples, and noted elevations in the relative proportion of immunosuppressive FoxP3+ regulatory T cells after infusion.

These findings suggest that CART-EGFRvIII activation induced a compensatory multifactorial immunosuppressive response in situ, say the investigators, adding that it could potentially be overcome with existing drugs that target immunosuppressive molecules.

Study author Donald ORourke, from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, USA, told the press: This is an early stage trial, but we are encouraged by the fact that the cells got into the brain, proliferated, and reduced the level of antigen with very little toxicity to the patients. We can build on this as a therapeutic option for these patients. It gives us clues on what to do next.

By Shreeya Nanda

medwireNews is an independent medical news service provided by Springer Healthcare. 2017 Springer Healthcare part of the Springer Nature group

Read the rest here:
Mutation-directed CAR T cell therapy feasible in recurrent glioblastoma - medwireNews

Biological bypass shows promise in coronary artery disease – Medical Xpress

August 8, 2017

A new gene therapy that targets the heart and requires only one treatment session has been found safe for patients with coronary artery disease, according to a successful trial carried out in Finland. Enhancing circulation in the oxygen-deficient heart muscle, the effects were visible even one year after the treatment.

The randomised, blinded, placebo-controlled phase 1/2a trial was carried out in collaboration between the University of Eastern Finland, Kuopio University Hospital and Turku PET Centre as part of the Centre of Excellence in Cardiovascular and Metabolic Diseases of the Academy of Finland.

The biological bypass is based on gene transfer in which a natural human growth factor is injected into the heart muscle to enhance vascular growth. The trial was the first in the world to use a novel vascular growth factor that has several beneficial effects on circulation in the heart muscle. The trial also developed a novel and precise method for injecting the gene into the oxygen-deficient heart muscle area. A customised catheter is inserted via the patient's groin vessels to the left ventricle, after which the gene solution can be injected directly into the heart muscle. The method is as easy to perform as coronary balloon angioplasty, which means that it is also suitable for older patients and patients who are beyond a bypass surgery or other demanding surgical or arterial operations.

The biological bypass constitutes a significant step forward in the development of novel biological treatments for patients with severe coronary artery disease. A new blood test biomarker was also discovered, making it possible to identify patients who are most likely to benefit from the new treatment.

The biological bypass was developed by Academy Professor Seppo Yl-Herttuala's research group at the A.I. Virtanen Institute for Molecular Sciences of the University of Eastern Finland. At the Kuopio University Hospital Heart Centre, Professor Juha Hartikainen was responsible for the trial.

Securing six million euros of funding from the European Union, research into the biological bypass will continue, and a new phase 2b trial will start at Kuopio University Hospital in early 2018. This trial will also include five other cardiology clinics from Denmark, the UK, Austria, Spain and Poland. The multi-centre trial will be coordinated by the Kuopio University Hospital Heart Centre, and the gene therapy drug will be manufactured in the clean room facilities of FinVector Therapies Ltd. in Kuopio.

Explore further: Novel mapping technique targets gene therapy to hibernating heart muscle

More information: Juha Hartikainen et al. Adenoviral intramyocardial VEGF-DNC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up, European Heart Journal (2017). DOI: 10.1093/eurheartj/ehx352

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View original post here:
Biological bypass shows promise in coronary artery disease - Medical Xpress

Sabathia on DL because of knee; Montgomery back – Daily Astorian

Yankees left-hander CC Sabathia was put on the 10-day disabled list because of right knee inflammation and left-hander Jordan Montgomery was recalled from Triple-A Scranton/Wilkes-Barre

The Associated Press

FILE - In this Aug. 1, 2017, file photo, New York Yankees starting pitcher CC Sabathia winds up during the first inning of the team's baseball game against the Detroit Tigers, at Yankee Stadium in New York. Sabatthia was put on the 10-day disabled list because of right knee inflammation and left-hander Jordan Montgomery was recalled from Triple-A Scranton/Wilkes-Barre. (AP Photo/Kathy Willens. File)

NEW YORK (AP) Forced to leave a start this week because of knee pain, CC Sabathia initially thought his career might be over. Now, the 37-year-old left-hander hopes to miss just one turn for the New York Yankees.

Sabathia was put on the 10-day disabled list Friday because of right knee inflammation, and rookie left-hander Jordan Montgomery was recalled from Triple-A Scranton/Wilkes-Barre to make Sabathia's start in Sunday night's series finale against Boston. Sabathia's DL trip was retroactive to Wednesday, a day after he allowed four runs in three innings at Toronto.

"When it first happened initially, I was freaking out," Sabathia said. "I was in a lot of pain and I felt like I was letting the team down."

Sabathia calmed down after he spoke with his wife, Amber, and an MRI showed no additional damage. He had cortisone and platelet rich plasma injections on Wednesday and felt well enough to play catch Thursday.

Sabathia hopes to throw a bullpen session Sunday, then get ready to return.

"I think it's going to be a question mark until he throws the bullpen," Yankees manager Joe Girardi said.

Sabathia originally was to have maintenance injections at regular intervals.

"We didn't because I felt great, so we didn't want to like kind of mess with it," he said.

Sabathia is 9-5 with a 4.05 ERA in 19 starts, including 14 scoreless innings in two wins against Boston. He pitches with a brace because of the knee, which was repaired with surgery in July 2014 and last October. He had not had pain injections since the last operation.

A knee replacement may be necessary when his playing days are over. He wants to be able to play golf and bowl.

Montgomery, 7-6 with a 4.05 ERA in 21 starts, was optioned to Scranton on Sunday, the consequence of the late-July acquisitions of Sonny Gray and Jaime Garcia. Montgomery never left town and threw a bullpen session Thursday at the Class A Staten Island Yankees.

Second baseman Starlin Castro, sidelined since July 21 by a strained right hamstring, and first baseman Greg Bird, who hasn't played since May 1 because of a right ankle injury that needed surgery last month, are likely to start minor league injury rehabilitation assignments next week.

"I'm just excited to play," Bird said.

New York also activated infielder Tyler Austin from the 10-day disabled list and optioned him to Triple-A. Austin had been sidelined since late June by a strained right hamstring and hit .217 (5 for 23) during a seven-game rehab assignment with the RailRiders.

___

More AP baseball: https://apnews.com/tag/MLBbaseball

Stay on topic - This helps keep the thread focused on the discussion at hand. If you would like to discuss another topic, look for a relevant article.

Share with Us - We'd love to hear eyewitness accounts, the history behind an article, and smart, constructive criticism.

Be Civil - It's OK to have a difference in opinion but there's no need to be a jerk. We reserve the right to delete any comments that we feel are spammy, off-topic, or reckless to the community.

Be proactive - Use the 'Flag as Inappropriate' link at the upper right corner of each comment to let us know of abusive posts.

Read more here:
Sabathia on DL because of knee; Montgomery back - Daily Astorian

Felix Hernandez, Hisashi Iwakuma remain hopeful of return to the Mariners’ rotation – Seattle Times

Both pitchers hope to help the Mariners in the final month of the season if not sooner.

Regardless of their performances prior to theirrespective injuries that landed them on the disabled list, the possible return of either Felix Hernandez or Hisashi Iwakuma or both to the Mariners rotation would be welcome addition. Its a unitthat has been hampered by injuries, lack of production and turnover. They would also be helpful in Seattles push for a spot in the postseason.

To be clear, neitherpitcher is returning in the coming days. And its not unfair to have a less than optimistic prognosis that neither would pitch again this season.

But they bothbelieve they will return.

Hernandez went on the disabledlist onSaturday for the second time this season with bursitis in his shoulder. He was placed on the disabled list on April 26 following a start in Detroit. He wouldnt return until June 22.

The last time it was in the back of my shoulder, he said. This time its in the front. They say its the same bursitis. Im not a doctor. I just tell them what I feel.

And he feels likethis discomfort isntnearly as bad as the first time.

They said three to four weeks, but I dont think so, he said. I can probably come back earlier. I just have to be careful not to rush it because of what could happen.They said its more inflamed than last time, but I feel better than last time. I dont understand it.

Hernandez recalled the days leading up to this DL appearance.

I felt fine before the last start in Texas, he said. The day I pitched in Texas I felt good. The next day I felt a little something in my shoulder. But I was fine before that. I was actually feeling really good.

That something in the shoulder didnt feel any better when he tried to play catch.

The next day in Texas, I was like, what is going on with my shoulder?' he said. I told them I cant throw a bullpen.

After examinations and tests from Dr. Edward Khalfayan, he received a platelet rich plasma (PRP) injection into the shoulder to speed up the healing process.

Im just hoping everything is good, he said. Im doing my treatment and waiting a few more days to see if I can play catch.

Hernandez is known to be a bit dour when hes on the disabled list and is not a fan of discussing his health. But he was in a good mood on Thursday with the team back in town. That wasnt the case when the injury first occurred.

I was so pissed, he said. Im still pissed. Im trying to calm myselfdown and, you know, smile to hide what I feel inside. Im just focused on getting healthy and help this team get to the promised land.

There was a belief that Iwakuma wouldnt return this season after experiencing multiple setbacks in his return from the shoulder inflammation that landed him on the DL on May 10. And he still may not. But hes going to keep working to do so. While the Mariners were on the road, Iwakuma threw three shorter bullpen sessions a major step back to being ready.

The plan is for him to throw an extended bullpen on Friday. If hecomes out of that healthy, Iwakuma would throw a simulated game next week. If that went well, he would head out on a rehab stint of at least two to three starts. If those went well, he might return to the rotation. Obviously, thats a lot of ifs that must go right to see him return.

It is tough to be be honest, he said through interpreter Antony Suzuki. It is whatit is. Its been a long process.But you have to go through your steps and go in the right directionand hopefully I will come back soon. The team is playing very well and you do have a strong feeling of wanting to help right now.

After receiving some injections and getting shutdown from his throwing program for a week in July, Iwakuma hasnt had any issues.

Better arm speed, better arm action, getting my mechanics and my deliveryto where I want to where its stress free on the shoulder, he said. As long as my mechanics are good, as long as Im not flying open, I dont feel anything. But when I do start flying open, I do feel tightness. Thats what Im working on right now.

Also

Mitch Haniger (facial laceration) participated in the pregame workout on Thursday, including taking batting practice on the field. He could go on a rehab assignment by next week. It could be a prolonged stint for Haniger, who was struggling before getting in the face by a95 mph fastball from Mets pitcher Jacob deGromm. With the Sept. 1 roster expansion looming, the Mariners could wait to activateHaniger from the DL, which would allow them to avoid another roster move to make room for him.

Veteran catcher Tuffy Gosewisch was outrighted to Class AAA Tacoma on Thursday. Gosewisch was designated for assignment on August 6 to make room on the 40-man roster for reliever Ryan Garton, who was acquired in a trade from the Rays.

Read more here:
Felix Hernandez, Hisashi Iwakuma remain hopeful of return to the Mariners' rotation - Seattle Times

New insight into how immune cells are formed – Medical Xpress

August 10, 2017

In contrast to what has been previously believed, development of blood stem cells into mast cells, a type of specialised immune cell, does not depend on stem cell factor. This has been demonstrated in a new collaborative study by researchers at Karolinska Institutet and Uppsala University, and published in the scientific journal Blood. The results could pave the way for new treatments for certain types of blood diseases.

Allergy and asthma affect a high percentage of the population. Mast cells are specialised immune cells that play an important role not only in these conditions but also in other diseases such as mastocytosis, a haematologic disease involving an increased number of mast cells. It has been commonly understood that the growth factor stem cell factor, which stimulates mast cell development, is essential for the formation of mast cells. Now researchers at Karolinska Institutet and Uppsala University have shown that this is not the case. The researchers analysed mast cells and their progenitors in blood from patients with chronic myeloid leukaemia, a disease of the blood.

"When the patients were treated with the drug imatinib (Glivec), which blocks the effect of stem cell factor, the number of mature mast cells dropped, while the number of progenitor cells did not change. We were thus able to conclude that mast cell progenitors did not require stem cell factor", says Professor Gunnar Nilsson at the Department of Medicine, Solna, and the Centre of Excellence for Systemic Mastocytosis at Karolinska Institutet, and visiting professor at the Department of Medical Sciences, Uppsala University, who led the study.

By culturing the mast cell progenitor cells present in blood, which are relatively uncommon (about 10 cells per million white blood cells), the researchers found that mast cell progenitors could survive, divide and partially mature without stem cell factor. Instead, development can take place with the factors interleukin 3 and 6.

"The study increases our understanding of how mast cells are formed and could be important in the development of new therapies, for example for mastocytosis for which treatment with imatinib/Glivec is not effective. One hypothesis that we will now test is whether interleukin 3 can be a new target in the treatment of mast cell-driven diseases", comments Joakim Dahlin, researcher at the Department of Medicine, Solna, at Karolinska Institutet and first author of the study.

Explore further: Proof-of principle study finds imatinib improves symptoms for patients with severe asthma

More information: Joakim S. Dahlin et al. KIT signaling is dispensable for human mast cell progenitor development, Blood (2017). DOI: 10.1182/blood-2017-03-773374

Journal reference: Blood

Provided by: Uppsala University

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Continue reading here:
New insight into how immune cells are formed - Medical Xpress

Microchip May Fix Damaged Cells And Organs, Scientists Say – CBS New York

August 8, 2017 6:48 PM

COLUMBUS, Ohio (CBSNewYork) It sounds like something out of a sci-fi novel a microchip that rescues injured or failing organs.

As CBS2s Dr. Max Gomez reported Tuesday, the breakthrough in regenerative medicine is actually being tested right now.

One of the hottest areas of medical research is using cells instead of drugs to treat diseases and injuries. But cellular therapies require finding or making the right type of cells, which can be difficult.

It turns out the body can do it on its own, with a little high-tech help.

The device is only about the size of a cufflink, but what it could represent is enormous. In a laboratory at the Ohio State University Wexner Medical Center, researchers demonstrated how it reprograms cells.

The chip is simply placed on an injured part of the body and a small electrical current is applied.

This process only takes less than a second and is non-invasive and then youre off, said Dr. Chan of Ohio State Wexner Medical Center. The chip does not stay with you, and the reprogramming of the cell starts.

That reprogramming turns skin cells into nearly any type of cell doctors might need to treat a patient a breakthrough technology in regenerative medicine.

For example, in a leg that is badly injured and lacks blood flow, doctors simply touch the chip to the leg and reprogram the skin to become functioning blood vessels.

And it will quickly shoot the DNA right into the cells, said Dr. James Lee of the Ohio State College of Engineering.

In many cases in seven days, you start seeing changes and these changes to our pleasant surprise persists, Dr. Sen said.

Within a week, there are active blood vessels and by the second week, the leg is saved.

It is important to note that the procedure has not yet been tested in humans. But after developing the concept, researchers were determined to test it in real life.

So we tried them on the mouse and put it on the skin, and you know what? It actually works, said Dr. James Lee of the Ohio State College of Engineering. It affects the entire tissue, not just the surface.

An image shows the mouses leg is injured, and vascular scans show there is little blood flow. But after one touch with the chip, in just three weeks, the blood flow was back and the injured leg was saved.

Our technology is not just limited to be used on the skin, Dr. Sen said. It can be used in other tissues within the body or outside the body, so on and so forth. So, skin is only one example.

In fact, in lab tests the chip even worked in the brain helping mice recover from strokes. In humans, it could allow doctors to grow brain cells on a persons skin under the guidance of their own immune system.

They could then harvest the cells and inject them into the brain to treat conditions such as Alzheimers disease and Parkinsons disease without any immune suppression drugs being necessary.

The electrical current actually opens up channels in the skin cells that allow the delivery of factors that are known to change the expression of certain genes in those cells. Better yet, the reprogramming doesnt have to be in a hospital setting because there is nothing invasive about it.

Follow this link:
Microchip May Fix Damaged Cells And Organs, Scientists Say - CBS New York